Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T13:30:31.651Z.
Calculation as of: 2026-10-06T13:30:31.651Z.
Quote observation: 2026-10-06T13:30:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 236ecad6846b0cc00793ea2ceb9f38c60eee5e96b58175726d9ae7432cdeb63e
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$662.34M
PS Ratio
7.20
TTM Avg
3326.30
3Y Avg
4783.92
5Y Avg
2925.64
Market Cap
$715.49M
PS Ratio
0.89
TTM Avg
1.85
3Y Avg
2.06
5Y Avg
2.04
Market Cap
$737.02M
PS Ratio
328.73
TTM Avg
191.08
3Y Avg
130.74
5Y Avg
130.74
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Annexon, Inc. (ANNX) | $689.78M | N/A | N/A | N/A | N/A |
| Faeth Therapeutics, Inc. (FTH)vs › | $695.00M | N/A | N/A | N/A | N/A |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $662.34M | 7.20 | 3326.30 | 4783.92 | 2925.64 |
| Helus Pharma Inc. (HELP)vs › | $688.02M | N/A | N/A | N/A | N/A |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $715.49M | 0.89 | 1.85 | 2.06 | 2.04 |
| Achieve Life Sciences, Inc. (ACHV)vs › | $724.77M | N/A | 2.39 | 2.16 | 5.43 |
| Aura Biosciences, Inc. (AURA)vs › | $647.51M | N/A | N/A | N/A | N/A |
| AngioDynamics, Inc. (ANGO)vs › | $645.20M | 2.02 | 1.66 | 1.27 | 1.62 |
| Anteris Technologies Global Corp. (AVR)vs › | $737.02M | 328.73 | 191.08 | 130.74 | 130.74 |
| Fulgent Genetics, Inc. (FLGT)vs › | $637.03M | 1.97 | 2.02 | 2.17 | 2.12 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-10 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-30 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-07 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-12 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
